What is the Return on Assets (ROA) of Theranexus this year?
The Return on Assets (ROA) of Theranexus is -0.94 undefined this year.
Theranexus ROA 2024
Theranexus ROA
-0.94
Ticker
ALTHX.PA
ISIN
FR0013286259
WKN
A2H6LX
In 2024, Theranexus's return on assets (ROA) was -0.94, a 73.15% increase from the -0.54 ROA in the previous year.
Theranexus Aktienanalyse
What does Theranexus do?
Theranexus SA is a French biotechnology company founded in Lyon in 2013. The company specializes in the development of drugs for the treatment of neurodegenerative diseases. It is one of the few companies specialized in the synthesis of drug candidates through the combination of molecules. The idea to create Theranexus arose from the collaboration between Mathieu Charveriat and Franck Mouthon, two experienced researchers who both worked at the CNRS laboratory at the University of Lyon. Their goal was to synthesize a new class of molecules that are more effective in the treatment of neuropsychiatric disorders such as depression, anxiety, narcolepsy, and Alzheimer's. The company specializes in two main areas: the development of novel drugs and the identification of drug candidates through the modulation of molecules that influence neuronal communication. Theranexus closely collaborates with academic partners to develop a wide range of therapeutic options for neurodegenerative diseases. The company focuses on the development of drugs that work in a unique and seamless way. Theranexus SA has a unique business model in the field of drug development. The company utilizes its innovative technology platform to combine and rearticulate molecules that can influence neuronal communication. The company aims to expand its technology platform and extend its research to other disease areas. The company operates two main activities: the development of drug candidates for the treatment of neurodegenerative diseases and the identification of new drug candidates through the modulation of molecules that influence neuronal communication. The company has recently developed a cathepsin S platform that focuses on the discovery of drugs and drug candidates for the treatment of neurodegenerative diseases. Cathepsin S is an enzyme involved in the formation of amyloid deposits that can play a role in Alzheimer's disease and other neurodegenerative diseases. Theranexus has also developed a platform for the formation of nanoparticles to enable drugs to have a longer half-life and reduce dosage. The company utilizes the platform to stabilize therapeutic molecules by modifying their chemical properties in the body. Theranexus's current products include ANX-368, a drug candidate for the treatment of narcolepsy, and THN102, a combination drug for the treatment of Parkinson's and sleep disorders. The drug candidate TNX-102 is being developed as a potential medication for the treatment of neuropathic pain. Overall, Theranexus SA aims to develop effective and innovative drugs for the treatment of neurodegenerative diseases. The company is committed to expanding its technology platform and continuing its research in other disease areas. Theranexus ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Theranexus's Return on Assets (ROA)
Theranexus's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Theranexus's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Theranexus's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Theranexus’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Theranexus stock
What was the ROA of Theranexus compared to the previous year?
The ROA of Theranexus has increased by 73.15% compared to the previous year.
What consequences do high ROA have for investors of Theranexus?
A high ROA is advantageous for investors of Theranexus, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Theranexus?
A low ROA can be unfavorable for investors of Theranexus as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Theranexus affect the company?
An increase in ROA of Theranexus can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Theranexus impact the company?
A reduction in the ROA of Theranexus can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Theranexus?
Some factors that can influence the ROA of Theranexus include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Theranexus important for investors?
The ROA of Theranexus is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Theranexus take to improve ROA?
To improve ROA, Theranexus can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Theranexus pay?
Over the past 12 months, Theranexus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Theranexus is expected to pay a dividend of 0 EUR.
What is the dividend yield of Theranexus?
The current dividend yield of Theranexus is .
When does Theranexus pay dividends?
Theranexus pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Theranexus?
Theranexus paid dividends every year for the past 0 years.
What is the dividend of Theranexus?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Theranexus located?
Theranexus is assigned to the 'Health' sector.
Wann musste ich die Aktien von Theranexus kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Theranexus from 10/2/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.
When did Theranexus pay the last dividend?
The last dividend was paid out on 10/2/2024.
What was the dividend of Theranexus in the year 2023?
In the year 2023, Theranexus distributed 0 EUR as dividends.
In which currency does Theranexus pay out the dividend?
The dividends of Theranexus are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Theranexus
Our stock analysis for Theranexus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Theranexus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
